Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial – The Lancet Respiratory Medicine Commentary: The right place for IL-1 inhibition in COVID-19 – The Lancet Respiratory Medicine   Commentary on Twitter NEW Research—Anakinra did not improve outcomes in patients with mild-to-moderate #COVID19 pneumonia […]

The post Randomized trial: Anakinra (IL-1 receptor antagonist) does not improve outcomes in patients with mild-to-moderate COVID-19 appeared first on Links Medicus.